laninamivir laninamivir laninamivir (cs-8958) is a neuraminidase inhibitor that is a drug used for the treatment and prophylaxis of influenzavirus a and influenzavirus b. it is currently in phase iii clinical trials. it is a long-acting neuraminidase inhibitor administered by nasal inhalation. laninamivirclinical dataroutes ofadministrationinhalationatc codej05ah04 (who) identifiers iupac name (4s,5r,6r)-5-acetamido-4-carbamimidamido-6--5,6-dihydro-4h-pyran-2-carboxylic acid cas number203120-17-6 npubchem cid502272chemspider439182 yuniib408iw3gl5chemblchembl466246 ycomptox dashboard (epa)dtxsid60942457 chemical and physical dataformulac13h22n4o7molar mass346.340 g·mol−13d model (jsmol)interactive image smiles o=c(o)c=1o((oc)(o)co)(nc(=o)c)(/n=c(\n)n)c=1 inchi inchi=1s/c13h22n4o7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20h,4h2,1-2h3,(h,16,19)(h,21,22)(h4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1 ykey:qnrrhyppqfelsf-cnyirltgsa-n y ny (what is this?) (verify) inavir laninamivir was approved for influenza treatment in japan in 2010 and for prophylaxis in 2013. it is currently marketed under the name inavir by daiichi sankyo. biota pharmaceuticals and daiichi sankyo co-own laninamivir. on 1 april 2011, barda awarded up to an estimated u$231m to biota pharmaceuticals (formerly biota holdings ltd) wholly owned subsidiary, biota scientific management pty ltd, for the advanced development of laninamivir in the us. it is under clinical evaluations in other countries.